title: Outcome of prosthetic joint infections treated with debridement and retention of components.
abstract: BACKGROUND
  Debridement and retention of the prosthesis represents an attractive surgical modality for treatment of prosthetic joint infection, but risk factors for treatment failure require clarification.
  
  
  METHODS
  We conducted a retrospective cohort analysis of all patients with a prosthetic joint infection who were treated with debridement and retention of the prosthesis at the Mayo Clinic (Rochester, Minnesota) between 1995 and 1999.
  
  
  RESULTS
  Debridement and retention of the prosthesis was the initial treatment modality for 99 episodes of prosthetic joint infection that occurred in 91 patients who presented to the Mayo Clinic during 1995-1999. A total of 32% and 23% of all episodes were due to Staphylococcus aureus and coagulase-negative staphylococci, respectively. The median duration of intravenous antimicrobial therapy was 28 days (range, 1-90 days). Oral antimicrobial suppression was used in 89% of the episodes, for a median duration of 541 days (range, 5-2673 days). Treatment failure occurred in 53 episodes during a median follow-up period of 700 days (range, 1-2779 days). The 2-year survival rate free of treatment failure was 60% (95% confidence interval [CI], 50%-71%). Variables associated with an increased risk of treatment failure in multivariable analysis included the presence of a sinus tract (hazard ratio, 2.84; 95% CI, 1.48-5.44; P = .002) and a duration of symptoms prior to debridement of > or = 8 days (hazard ratio, 1.77; 95% CI, 1.02-3.07; P = .04).
  
  
  CONCLUSIONS
  Debridement and retention of the prosthesis is a common surgical modality at our institution to treat prosthetic joint infection. Risk factors independently associated with treatment failure include the presence of a sinus tract and duration of symptoms prior to debridement of > or = 8 days.
authors.affiliation: Division of Infectious Diseases, Medical University of South Carolina, Charleston, USA.
authors.forename: C E
authors.initials: CE
authors.lastname: Marculescu
authors.forename: E F
authors.initials: EF
authors.lastname: Berbari
authors.forename: A D
authors.initials: AD
authors.lastname: Hanssen
authors.forename: J M
authors.initials: JM
authors.lastname: Steckelberg
authors.forename: S W
authors.initials: SW
authors.lastname: Harmsen
authors.forename: J N
authors.initials: JN
authors.lastname: Mandrekar
authors.forename: D R
authors.initials: DR
authors.lastname: Osmon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019643:Arthroplasty, Replacement / Q000009:adverse effects; D015331:Cohort Studies; D003646:Debridement; D020878:Device Removal; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007595:Joint Prosthesis / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016459:Prosthesis-Related Infections / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000628:therapy*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents